Treatment Success Rates:
Beyond 5-Year Survival
Moving to MRD Negativity, Functional Cure, and Biomarker-Stratified Success — the new gold standards in oncology.
Redefining "Success" in Modern Oncology
For decades, oncology measured success using a single, blunt metric: the 5-Year Overall Survival (OS) Rate. But in the era of CAR-T cell therapy, Antibody-Drug Conjugates (ADCs), and precision immunotherapy, this metric is obsolete.
Today, a "successful" treatment is defined by three advanced clinical endpoints:
- MRD Negativity (Minimal Residual Disease): The absence of cancer cells at a sensitivity of 1 in 100,000 to 1 in 1,000,000 cells — the deepest measurable response.
- The "Tail on the Curve": A plateau in Kaplan-Meier survival curves indicating a functional cure — the patient will likely not relapse.
- Biomarker-Stratified Efficacy: Success is no longer an average; it is precisely predicted by molecular profiling (PD-L1 CPS, HER2-IHC, TMB, MSI-H).
The 2025/2026 Global Success Matrix
Data synthesized from ASCO, ESMO, ASH 2024-2025 presentations, and pivotal trial publications.
A. Hematologic Malignancies: The Era of Functional Cures
| Cancer Type | Treatment Modality | Key Trial | ORR | CR | MRD Negativity | The "Cure" Metric |
|---|---|---|---|---|---|---|
| R/R DLBCL | CAR-T (Axi-cel) 2L | ZUMA-7 (5-yr FU) | 83% | 65% | ~60% (10⁻⁴) | 5-Year OS: ~45-50%. Curve plateaus at 3 years — functional cure in nearly half. |
| R/R B-ALL (Pediatric) | CAR-T (Tisa-cel) | ELIANA / Chinese RWE | 81-89% | 75-83% | >85% (10⁻⁵) | EFS at 4 yrs: >70% when bridged to allo-SCT. |
| Relapsed Myeloma | CAR-T (Cilta-cel) 2L | CARTITUDE-4 | 95% | 83% | >83% (10⁻⁵) | At 2 years, >80% remain progression-free. Redefining MM as potentially curable. |
| R/R Multiple Myeloma | Bispecific (Teclistamab) | MajesTEC-1 | 63% | 58% | ~50% (10⁻⁴) | Durable responses in heavily pretreated (median 4 prior lines). |
B. Solid Tumors: The Precision & ADC Revolution
| Cancer Type | Treatment Modality | Key Trial | ORR | PFS / OS Milestone | The Paradigm Shift |
|---|---|---|---|---|---|
| Metastatic NSCLC | IO + Chemo (Pembro) | KEYNOTE-189 (5-yr) | 45-60% | 5-Year OS: 23-25% | Before IO, 5-yr OS for mNSCLC was <5%. Now we have a "long-tail" of survivors. |
| HER2-Low Breast Cancer | ADC (T-DXd / Enhertu) | DESTINY-Breast04 | 52% | Median PFS: 13.2 mos | Created entirely new breast cancer subtype (IHC 1+ or 2+/ISH-) benefiting from HER2 therapy. |
| Advanced HCC (PVTT) | HAIC + Lenvatinib + PD-1 | Chinese Phase III | 60-70% | Median OS: >16 mos | China Exclusive: Chinese HAIC protocols vastly outperform Western Sorafenib alone (ORR <15%). |
| Gastric (CLDN18.2+) | CAR-T (CT041) | Phase I/II Chinese | 60-80% | Early-phase data | First-in-class success in difficult solid tumor. Most promising solid tumor CAR-T globally. |
| TNBC (PD-L1 CPS ≥10) | IO + Chemo (Pembro) | KEYNOTE-522 (Early) | pCR: 64.8% | pCR predicts long-term EFS | Pathologic Complete Response is the new metric for early-stage success. |
The Biomarker Imperative — Why Averages Lie
If a drug has a 40% Overall Response Rate, it means 100% of the right patients responded, and 0% of the wrong patients responded. Success rates are entirely dependent on molecular matching.
🧬 Immunotherapy (PD-1/PD-L1)
Success rates for Pembrolizumab in Gastric/NSCLC jump from <15% (CPS <1) to >60% (CPS ≥10).
- TMB-High (≥10 mut/Mb): 2-3x higher response to checkpoint inhibitors
- MSI-H / dMMR: Universal biomarker — >70% response with IO in colorectal and endometrial cancers
💊 Antibody-Drug Conjugates
The DESTINY trials proved that even HER2-Low (IHC 1+) and HER2-Ultra-Low express enough receptor for T-DXd to internalize and kill.
- Trop-2 Expression: Critical for predicting success of Sacituzumab Govitecan in TNBC
- Claudin18.2: Emerging target — >60% ORR in gastric cancer with CT041 CAR-T
🧫 CAR-T Cell Therapy
Flow cytometry must confirm high expression of CD19, BCMA, or CD22. Low antigen density predicts early relapse via antigen escape.
- T-Cell Fitness: Patients with high CD4/CD8 ratios and low exhaustion markers have >30% higher success rate with CAR-T
- Prior Chemo Lines: Each line damages T-cells — earlier CAR-T use yields higher success
Geographic Efficacy — China vs. USA vs. Europe
A critical question for international patients: Is the success rate of treatment in China comparable to the US or Europe? The short answer: For approved indications, the efficacy data is statistically non-inferior. For novel targets, China is often ahead.
| Modality | USA (FDA) | China (NMPA) | Clinical Equivalency & Success Rates |
|---|---|---|---|
| CD19 CAR-T (DLBCL) | Axi-cel (Yescarta) | Relma-cel (Fosun Kite) | Equivalent. Approved based on Chinese cohort of global ZUMA trial. ORR and CR rates identical (~80% / ~60%). |
| BCMA CAR-T (Myeloma) | Cilta-cel (Carvykti) | Idecabtagene / Local variants | Highly Comparable. Nanjing Legend (co-developer of Cilta-cel) produces domestic versions with >90% ORR in R/R MM. |
| First-Line HCC | Atezo + Bev (IMbrave150) | Donafenib / HAIC + IO | Divergent. IMbrave150 OS 19.2 months. Chinese HAIC+IO protocols show >60% ORR in advanced PVTT cases where Western IO fails. |
| Solid Tumor CAR-T | Phase I only (Limited) | Phase I/II (Active) | China Leads. China has >100 active solid tumor CAR-T trials (Gastric, Liver, Pancreatic). US has virtually no late-stage solid tumor CAR-T approvals. |
The "Landing Speed" Advantage: Success in oncology is also about time. In the US, the wait for CAR-T manufacturing and insurance approval can be 4-8 weeks. In China, the "vein-to-vein" time is often 14-21 days. For aggressive leukemias, this speed directly translates to a higher real-world success rate because the patient doesn't progress while waiting.
Visualizing the Data
Key data visualizations that make this page the ultimate reference for understanding oncology success.
📈 The "Tail on the Curve" (Kaplan-Meier)
Show the Chemo curve steadily dropping to near zero. Show the CAR-T curve dropping initially (early toxicity/progression) but then flattening out completely after 24 months. Highlight the flat section as the "Functional Cure Zone" — where relapses become rare events.
🔬 The MRD Funnel (Hematology)
A funnel chart showing: Morphological CR (Microscope) → Flow Cytometry (10⁻⁴) → NGS/PCR (10⁻⁵ to 10⁻⁶). CAR-T pushes 80% of patients into the deepest end of the funnel, compared to <20% for standard chemo — the reason for durable remissions.
🧬 Biomarker Heatmap (Solid Tumors)
A color-coded matrix: Rows = Cancer Types (NSCLC, Gastric, Breast). Columns = Biomarkers (PD-L1 High, TMB High, HER2-Low, MSI-H). Color: Green (>60%), Yellow (30-60%), Red (<30%). This visually proves that "success" depends on the biomarker, not the organ.
The Reality of Treatment Failure — Salvage Pathways
No medical page is trustworthy if it only discusses success. We address what happens when primary treatment fails.
🔄 The "Antigen Escape" Problem in CAR-T
In ~30% of B-cell malignancies, cancer cells mutate and stop expressing CD19. CAR-T cells can no longer "see" the tumor, leading to relapse.
The Solution: Dual-target CAR-T (CD19 + CD22). Chinese trials show re-treatment with dual-target CAR-T achieves a second CR rate of >70% in patients who relapsed after single-target CAR-T.
🧊 The "Cold Tumor" Problem in Immunotherapy
60% of solid tumors are "immunologically cold" (no T-cells inside). Immunotherapy fails completely without T-cell infiltration.
The Solution: Combination therapy. Anti-angiogenic drugs (Lenvatinib) or localized therapies (TACE, HAIC, Radiation) normalize tumor blood vessels and recruit T-cells, then Immunotherapy. This converts "cold" to "hot" tumors, increasing IO success rates from <15% to >50%.
Actionable Takeaways for Patients and Physicians
👤 For the Patient
- Demand Molecular Profiling: Never accept a treatment plan based solely on organ of origin. Insist on NGS and IHC biomarker testing.
- Ask About MRD: If receiving treatment for blood cancer, ask: "Are we tracking MRD? What is the sensitivity of the test?"
- Consider the "Time Factor": If your disease is rapidly progressing, a slightly less "famous" therapy available immediately (off-the-shelf NK cells or Chinese CAR-T trials) may yield a higher real-world success rate than waiting 2 months for customized Western CAR-T.
👨⚕️ For the Referring Physician
When you refer a patient to our network for advanced therapies, we do not guess. We match the patient's exact molecular profile to the centers with the highest biomarker-stratified success rates.
- We provide you with the exact trial protocols
- We ensure continuity of care with standardized discharge summaries
- We focus on MRD-negative outcomes, not just temporary radiographic shrinkage
Want to Know Your Personalized Success Rate?
Submit your medical records. Our oncology team will review your molecular profile, prior treatments, and clinical data — and provide an evidence-based assessment of your likely outcomes with the best available therapies.
Free • Confidential • 48-Hour Response • No Obligation
Scientific References & Data Sources (2024-2026)
- ZUMA-7 Long-Term Follow-Up: Locke FL, et al. NEJM Evidence 2024; 5-year outcomes of Axi-cel in 2nd-line DLBCL.
- CARTITUDE-4 Trial: Rodriguez-Otero P, et al. NEJM 2024; Cilta-cel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma.
- KEYNOTE-189 5-Year Update: Garon EB, et al. JCO 2024; Pembrolizumab plus chemotherapy for metastatic NSCLC.
- DESTINY-Breast04: Modi S, et al. NEJM 2022/2023 updates; Trastuzumab deruxtecan in HER2-Low breast cancer.
- Chinese HAIC + IO Protocols: Lyu N, et al. JAMA Oncology / Lancet regional updates; HAIC + Lenvatinib + PD-1 for HCC with PVTT.
- CT041 (Claudin18.2 CAR-T): Qi C, et al. ASCO/GITC 2024; First-in-human data for solid tumor CAR-T in gastric cancer.
- NMPA vs FDA Equivalency: China NMPA Center for Drug Evaluation (CDE) Annual Reports 2024-2025; ICH-GCP alignment data.